Ohio, United States 16, Oct 2020. Qualtran signed an agreement with Exhalent Diagnostic of Taylorsville, United States for field testing of devices designed for COVID-19 and tuberculosis through breath based diagnostic devices in India.

Exhalent Diagnostics is on the fast track to field test its COVID-19 and tuberculosis diagnostic device, through the World Health Organization, early this year. Foster management professor & entrepreneur Daniel Olson runs biotech company Exhalent Diagnostic, believes the proof-of-concept would have opened new doors to fast-track evaluation of the breath-based sensor for CORONAVirus & Tuberculosis diagnosis during early stages of infections. Exhalent Diagnostic co-founder Blain Chappell has begun recalibrating the diagnostic platform to detect the CORONA Virus that causes infection. It promises to be quicker, cheaper, more accurate and less invasive than other existing methods.

“We are excited about the opportunities in India with Exhalent Diagnostic and their low cost less invasive diagnostic device during this COVID-19 pandemic will provide high investigating potential to the new emerging therapies for COVID-19 and Tuberculosis diagnosis” said Mr. Sandeep Malik, President of Qualtran. Also, we look forward to working closely with Exhalent diagnostic in realizing full potential from these emerging biotech companies in the entire Asian Market.